Alembic Pharmaceuticals gets USFDA nod for pain relief ointment -Xylocaine

NEW DELHI: Alembic Pharmaceuticals Monday said its joint venture Aleor Dermaceuticalshas received approval from the US health regulator for Xylocaine ointment, used for temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin and insect bites.

"Aleor Dermaceuticals has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Lidocaine ointment USP, 5 per cent," Alembic Pharmaceuticals said in a BSE filing.

Aleor is a 60:40 joint venture between Alembic and Orbicular Pharmaceutical Technologies Pvt Ltd (Orbicular) formed in Apr'16 focusing on commercialising dermatology products globally.

The approved product is therapeutically equivalent to AstraZeneca Pharmaceuticals' Xylocaine ointment, 5 per cent.

Quoting IQVIA data, Alembic Pharmaceuticals said Lidocaine ointment has an estimated market size of USD 97 million for twelve months ending December 2017.

Alembic has a cumulative total of 79 ANDA approvals (66 final approvals and 13 tentative approvals) from USFDA, including this first ANDA approval for Aleor.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.

Also Read: Alembic Pharma gets 4 observation by USFDA for Panelav facility